However, treatment of PC3 cells with the small molecule Rho Activator II [40] had no effect on the level of Rac1 activation, therefore demonstrating that the pool of hyperactive Rac1 in these prostate cancer cells is also insensitive to negative regulation by RhoA (Figure S2B). Here, RAC1 is linked to prostate carcinoma.